Results 161 to 170 of about 39,591 (271)

Intravitreal injections of corticosteroid and the risk of central serous chorioretinopathy. [PDF]

PLoS One
Song JR, Woo SJ.
europepmc   +1 more source

Neovascular age‐related macular degeneration without drusen

Acta Ophthalmologica, Volume 104, Issue 3, Page e300-e311, May 2026.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks, Elon H. C. van Dijk, Husein Ghalayini, Somayeh Bazdar, WeiFeng Yu, Suzanne Yzer, José P. Martinez Ciriano, Reinier O. Schlingemann, Roselie M. H. Diederen, Camiel J. F. Boon   +9 more
wiley   +1 more source

Travel-associated emissions of intravitreal injections. [PDF]

Graefes Arch Clin Exp Ophthalmol
Yang-Seeger D, Schellstede A, Pauleikhoff LJB, Spitzer MS, Birtel J.   +4 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Mobile Laminar Airflow for Intravitreal Injections: Reducing Microbial Load at the Instrument Field. [PDF]

J Clin Med
Satriani V, Boccia G, Santella B, Cione F, Donato A, Santoro E, De Rosa A, De Bernardo M, Rosa N.   +8 more
europepmc   +1 more source

Optimizing Oligonucleotide Therapeutics: A Model‐Informed Drug Development Perspective

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Oligonucleotide therapies have emerged as a powerful therapeutic class, providing novel solutions for diverse diseases through antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and aptamers that specifically target and modulate gene expression or protein function. However, oligonucleotide development faces distinct challenges,
Ye Yuan, Vishnu Sharma, Venkatesh Atul Bhattaram, Xiaolei Pan, Justin Earp, Yun Wang, Jiang Liu, Hao Zhu   +7 more
wiley   +1 more source

Attenuation of Oxygen‐Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG‐2 With an Antibody

Genes to Cells, Volume 31, Issue 3, May 2026.
The effects of intraocular administration of neutralizing antibodies against VEGFA, ANG‐2, or bispecific to these two factors on pathological findings were examined in the oxygen‐induced retinopathy (OIR) mouse model. The antibody to VEGFA or ANG‐2 attenuated oxygen‐induced neovascularization and inflammation, and the bispecific antibody more ...
Hirokazu Oohashi, Toshiro Iwagawa, Hiroto Abe, Chihiro Kawaji, Yuta Inokuchi, Tetsuhiro Soeda, Kosuke Saita, Makoto Aihara, Sumiko Watanabe   +8 more
wiley   +1 more source

Effect of prior intravitreal injections on the risk of posterior capsule rupture during cataract surgery: a single-surgeon matched case-control study. [PDF]

BMC Ophthalmol
Caglar C.
europepmc   +1 more source

Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin‐like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling

Journal of Diabetes Investigation, Volume 17, Issue 5, Page 751-765, May 2026.
Molecular mechanism of synergistic antagonism of ANGPTL4 and VEGF by ginsenoside Rg3 combined with ranibizumab, regulating the NRP/RhoA pathway to inhibit macular edema. ABSTRACT Aims This study investigated the molecular mechanisms by which ginsenoside Rg3 combined with ranibizumab alleviates diabetic macular edema (DME), focusing on antagonizing ...
Jiexin Yu, Xingyu Li, Yanli Liu
wiley   +1 more source

Intravitreal Cidofovir Injection for Refractory End‐Stage Glaucoma and Vision Loss in Silicone Oil‐Filled Eyes Following Retinal Reattachment Surgery in Dogs: Four Cases

Veterinary Ophthalmology, Volume 29, Issue 3, May 2026.
ABSTRACT Objective To describe the clinical outcome of intravitreal cidofovir injection for palliative management of refractory end‐stage glaucoma and vision loss in silicone oil‐filled eyes following retinal reattachment surgery in dogs. Procedures Medical records of dogs that underwent a single intravitreal cidofovir injection for pharmacologic ...
Sunhyo Kim, Jaeho Shim
wiley   +1 more source